Ablation is recommended by international guidelines for the treatment of HCC.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Clinical RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015.JAMA Oncol. 2017; 3: 1683-1691
- EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol. 2018; 69: 182-236
- HCC-associated liver transplantation: where are the limits and what are the new regulations?.Visc Med. 2016; 32: 263-271
- Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.Ann Surg. 2015; 261: 947-955
- Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.Hepatology. 2018; 68: 723-750
- The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.Liver Transpl. 2004; 10: S115-S120
- Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia.Int J Hyperthermia. 2003; 19: 267-294
- The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review.Ann Surg. 2009; 249: 20-25
- Value of radiofrequency ablation in the treatment of hepatocellular carcinoma.World J Gastroenterol. 2014; 20: 5987-5998
- A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg. 2006; 243: 321-328
- Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey.J Hepatol. 2013; 59: 89-97
- Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with meta-analysis and trial sequential analysis.Radiology. 2018; 287: 461-472
- Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.Onco Targets Ther. 2018; 11: 6555-6567
- Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection.HPB (Oxford). 2018; 20: 546-554
- Microwave tissue ablation: biophysics, technology, and applications.Crit Rev Biomed Eng. 2010; 38: 65-78
- Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis.World J Surg Oncol. 2017; 15: 126
- Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma.Clin Radiol. 2017; 72: 136-140
- Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial.Lancet Gastroenterol Hepatol. 2018; 3: 317-325
- Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications.Eur Radiol. 2018; 29: 654-662
- Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma.Hepatology. 2015; 61: 1579-1590
- Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox.Ann Surg Oncol. 2015; 22: 1294-1300
- Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria.PLoS One. 2015; 10: e0123065
- Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series.Radiology. 2017; 284: 877-886
- Percutaneous irreversible electroporation: long-term survival analysis of 71 patients with inoperable malignant hepatic tumors.Sci Rep. 2017; 7: 43687
- Bile duct injury after irreversible electroporation of hepatic malignancies: evaluation of MR imaging findings and laboratory values.J Vasc Interv Radiol. 2016; 27: 96-103
- Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).HPB (Oxford). 2016; 18: 593-599
- Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives.J Hepatocell Carcinoma. 2017; 4: 49-58
- Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.Hepatology. 2014; 60: 192-201
- Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study.Radiology. 2017; 283: 895-905
- Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma.Radiology. 2018; 287: 1050-1058
- Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.Abdom Radiol (NY). 2018; 43: 1825-1836
- Stereotactic body radiotherapy for primary hepatocellular carcinoma.Int J Radiat Oncol Biol Phys. 2011; 81: e447-e453
- Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.J Clin Oncol. 2013; 31: 1631-1639
- Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.Acta Oncol. 2014; 53: 399-404
- Hepatobiliary cancers (version 4.2018).(Available at:) (Accessed October 25, 2018)
- Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.J Clin Oncol. 2016; 34: 460-468
- Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.J Hepatol. 2017; 67: 92-99
- Complications of high intensity focused ultrasound for patients with hepatocellular carcinoma.Technol Cancer Res Treat. 2009; 8: 217-224
- Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.Korean J Intern Med. 2018; 33: 1093-1102
- Fiducial marker placement for stereotactic body radiation therapy via convex probe endobronchial ultrasound: a case series and review of literature.J Thorac Dis. 2018; 10: 1972-1983
- Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region.Technol Cancer Res Treat. 2012; 11: 591-597
- Proton therapy for hepatocellular carcinoma: current knowledges and future perspectives.World J Gastroenterol. 2018; 24: 3090-3100
- IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies.Int J Mol Sci. 2018; 19 ([pii:E1766])
- Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.Radiology. 2003; 228: 235-240
- A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.Gastroenterology. 2005; 129: 122-130
- Transarterial ethanol ablation combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus.Hepat Mon. 2016; 16: e37584
- Ablative chemoembolization for hepatocellular carcinoma: a prospective phase I case-control comparison with conventional chemoembolization.Radiology. 2018; 287: 340-348
- Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.Radiology. 2014; 270: 607-620
- Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas.Liver Int. 2014; 34: e136-e143
- Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study.Oncotarget. 2018; 9: 17483-17490
- Laser ablation of liver tumors: an ancillary technique, or an alternative to radiofrequency and microwave?.World J Radiol. 2017; 9: 91-96
- Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial.J Clin Oncol. 2013; 31: 426-432
- Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis.Oncotarget. 2018; 9: 7557-7566
- Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials.Int J Clin Exp Med. 2015; 8: 10388-10400
- Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma.Eur J Cancer. 2010; 46: 2513-2521
- High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: long-term follow-up and clinical analysis.Eur J Radiol. 2011; 80: 662-669
- Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.BMC Cancer. 2016; 16: 834
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2015; 16: 1344-1354
- Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions.Clin Cancer Res. 2018; 24: 73-83
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 56-66
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet. 2017; 389: 2492-2502
- Abscopal effects and yttrium-90 radioembolization.Cardiovasc Intervent Radiol. 2016; 39: 1076-1080
- Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma.Gut. 2019; 68: 335-346
- Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis.Cardiovasc Intervent Radiol. 2011; 34: 424-430
- The local liver ablation with pulsed electric field stimulate systemic immune reaction against hepatocellular carcinoma (HCC) with time-dependent cytokine profile.Cytokine. 2017; 93: 44-50
- Early immunologic response of irreversible electroporation versus cryoablation in a rodent model of pancreatic cancer.J Vasc Interv Radiol. 2018; 29: 1764-1769
- Allogenic natural killer cell immunotherapy combined with irreversible electroporation for stage IV hepatocellular carcinoma: survival outcome.Cell Physiol Biochem. 2018; 48: 1882-1893
- Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer.Cardiovasc Intervent Radiol. 2019; 42: 48-59
- Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery.Front Oncol. 2017; 7: 96
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nat Med. 2013; 19: 329-336
- Recent advances in tumor ablation for hepatocellular carcinoma.Liver Cancer. 2015; 4: 176-187
- Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation.Exp Ther Med. 2016; 12: 1345-1348
- Microwave ablation of the liver abutting the stomach: insulating effect of a chitosan-based thermosensitive hydrogel.Int J Hyperthermia. 2014; 30: 126-133
- Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.Diagn Interv Radiol. 2018; 24: 219-224
- Analysis of patients with rapid aggressive tumor progression of hepatocellular carcinoma after percutaneous radiofrequency ablation.Hepatogastroenterology. 2009; 56: 1689-1695
- Hepatic radiofrequency ablation-induced stimulation of distant tumor growth is suppressed by c-Met inhibition.Radiology. 2016; 279: 103-117
- Neoadjuvant locoregional therapy and recurrent hepatocellular carcinoma after liver transplantation.J Am Coll Surg. 2017; 225: 28-40
Article info
Publication history
Published online: June 06, 2019
Footnotes
Disclosures: B.B. Toskich is an advisor to Boston Scientific, BTG, and Ethicon.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
